News from grünenthal group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 10, 2019, 06:46 ET Jan Adams Appointed Chief Scientific Officer for Grünenthal

Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective ...


May 02, 2019, 08:52 ET Five Young Scientists Win EFIC-Grünenthal Grant 2018

The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as...


Jan 22, 2019, 05:25 ET Grünenthal: Fabian Raschke Appointed Chief Financial Officer (CFO)

Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will...


Dec 14, 2018, 02:00 ET Grünenthal and OnDosis Team Up for Individualised Dosing of Oral Drugs in Pain Management to Increase Patient Safety

Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis' technology for prescription...


Nov 14, 2018, 03:27 ET Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to...


Nov 05, 2018, 07:04 ET Grünenthal Acquires Global Rights for Qutenza®

Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for ...


Oct 30, 2018, 04:34 ET Grünenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium and Vimovo

Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management...


Jun 18, 2018, 07:18 ET EFIC: Fresh Ideas in Pain Research

Creative approaches to research by young scientists provide opportunity for new and challenging thinking to benefit patients who suffer from pain. To ...


Jun 12, 2018, 07:25 ET Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate...


Feb 01, 2018, 06:11 ET Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP)...


Jan 23, 2018, 06:50 ET Grünenthal distribuirá, promocionará y venderá productos de Salud Femenina de MSD en varios países de Latinoamérica

Grünenthal ha anunciado hoy que ha firmado un acuerdo con MSD (nombre comercial de Merck & Co., Inc., Kenilworth, N.J., EE.UU.) para la distribución, ...


Jan 23, 2018, 05:58 ET Grünenthal to Distribute, Promote, and Sell MSD's Women's Health Products in Several Countries in Latin America

Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for...


Jan 15, 2018, 12:00 ET Grünenthal and Mundipharma Enter Commercial Partnership in China

Grünenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement. Under its terms, Mundipharma will market ...


Dec 05, 2017, 01:06 ET New Partnership for the Commercialization of Nucynta® in the U.S. Territory

The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc.,...


Nov 16, 2017, 04:41 ET Research Consortium led by Grünenthal Receives € 2 Million Grant from the European Fund for Regional Development and the State of North Rhine-Westphalia

- "LifeSciences.NRW" grant to support the discovery and development of new pain relief drugs - Grünenthal founded and leads the Consortium to which...


Sep 07, 2017, 12:00 ET Aging Demographics Require Novel Ideas in Pain Research

Significant unmet medical needs in the field of pain in Europe have made pain research more relevant than ever. On the occasion of the congress of...


Sep 01, 2017, 13:30 ET Mark Fladrich asume su cargo como nuevo CCO del Grünenthal Group

Responsabilidad para toda la Global Commercial Organization Fortalecimiento de la interfaz entre Commercial e Investigación y Desarrollo (I&D) para...


Sep 01, 2017, 00:00 ET Mark Fladrich Takes Office as the New CCO of the Grünenthal Group

Responsibility for the entire Global Commercial Organization Strengthen the interface between Commercial and Research and Development (R&D) to...


Jul 07, 2017, 09:42 ET Grünenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)

The new research project NGN-PET was launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership...


Jun 07, 2017, 04:00 ET Grünenthal Enters Agreement with AstraZeneca to Acquire Global Rights to Migraine Treatment Zomig® (Zolmitriptan)

This acquisition further strengthens Grünenthal's leading position in pain indications With migraine, Grünenthal adds another major pain indication...


May 10, 2017, 05:58 ET Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward

Grünenthal's new Innovation Hub in Greater Boston, U.S., shall accelerate easier access to and close collaboration with leading scientists and...


May 09, 2017, 08:58 ET Mark Fladrich Appointed New Chief Commercial Officer (CCO) at Grünenthal

The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire...


Apr 07, 2017, 11:49 ET The Grünenthal Group Today Announced the Acquisition of the Company Adhesys Medical to Expand its Pipeline of Medical Devices for its Business with Surgeons

The acquisition of Adhesys Medical and its highly innovative pipeline of surgical sealants, together with the underlying technology platform, allows...


Dec 16, 2016, 06:48 ET Grünenthal Receives Breakthrough Therapy Designation From U.S. FDA for Neridronic Acid for the Treatment of CRPS

Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a...


Dec 12, 2016, 02:00 ET Grünenthal to Acquire Commercialization Rights of Qutenza® in Europe from Astellas Pharma Europe

Grünenthal Group today announced that it has entered into a definitive agreement with Astellas Pharma Europe Ltd., ("Astellas Pharma Europe"), the...